We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Care Health America - WHPM

Care Health America – WHPM is an international medical device manufacturer specializing in the development and sale o... read more Featured Products: More products

Download Mobile App




Protein Levels May Help Diagnose Bipolar Disorder

By LabMedica International staff writers
Posted on 21 Dec 2015
A series of proteins have been discovered that could be diagnostic markers to identify bipolar I disorder and if this discovery sample can be validated through replication, these markers may help as a diagnostic tool for psychiatrists treating mood disorders.

It is critical to differentiate bipolar disorder from other mood disorders as the treatments differ and a medication suited to one condition may be dangerous to patients with another. More...
Up to now psychiatrists have relied on observed symptoms and patient assessments based on interviews, and that information is then compared to established diagnostic criteria.

Psychiatrists at the Mayo Clinic, Rochester, MN, USA) recruited study volunteers, 46 had been diagnosed with bipolar I (history of mania) depression, 49 with bipolar II (history of hypomania) depression, and 52 with unipolar depression. They were compared with 141 individuals without mood disorders, known as controls. A urine drug screen was performed by study personnel using a One Step Multi-Drug Urine Test Panel kit (W.H.P.M.; Irwindale, CA, USA) to screen for any current illicit substances after participants signed the study consent form.

About 288 serum samples (141 controls, 52 unipolar, 49 bipolar II, 46 bipolar I) were randomized to four plates (72 wells × 4). There was no difference in plate by group allocation and age of sample from collection to analysis. The 320 proteins (were measured in 250 μL serum samples using the DiscoveryMAP multiplexed immunoassays (Myriad RBM Inc.; Austin, TX, USA).

In total, after adjusting for variables, 73 proteins were found to differ among the four groups studied. The results however showed a significant difference for six proteins in individuals with bipolar I depression (BP-1) versus controls. These were growth differentiation factor 15 (GDF-15), hemopexin (HPX), hepsin (HPN), matrix metalloproteinase-7 (MMP-7), retinol-binding protein 4 (RBP-4) and transthyretin (TTR). GDF-15, RBP-4 and TTR were good predictors of BP-I with ROC-AUC of 0.81, while HPX and HPN were fair predictors of BP-I with ROC-AUC of 0.74 and 0.78, respectively.

Mark A. Frye, MD, head of psychiatry and lead author of the study said, “The potential of having a biological test to help accurately diagnose bipolar disorder would make a huge difference to medical practice. It would then help clinicians to choose the most appropriate treatment for hard-to-diagnose individuals.” The study was published on December 8, 2015, in the journal Translational Psychiatry.

Related Links:

Mayo Clinic 
W.H.P.M.
Myriad RBM Inc. 



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.